pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection
Merck KGaA, Darmstadt
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt is a pharma organization headquartered in Darmstadt, DE. Primary therapeutic focus areas include Carcinoma, Renal Cell, Human Immunodeficiency Virus (HIV) Infection, Systemic Lupus Erythematosus, So
Frankfurter Str. 250, Darmstadt, 64293, DE HQ
7,364 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Frankfurter Str. 250, Darmstadt, 64293, DE
- Employees
- 7,364
- Programs
- 63
- Drugs
- 50
- Patents
- 0
MK-6194
Phase 2 · mab · Systemic Lupus Erythematosus
MK-6194 for Systemic Lupus Erythematosus is a Phase 2 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Internal code 6194-006
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Phase 2
- Modality
- mab
- Indication
- Systemic Lupus Erythematosus
- Status
- terminated
- Trials
- 1